Blocking MIF secretion enhances CAR T-cell efficacy against neuroblastoma
European Journal of Cancer · 2025
DOI: 10.1016/j.ejca.2025.115263 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Josephine G M Strijker und 26 weiteren Autor:innen. Beteiligte Einrichtung: Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Neuroblastoma, Immunotherapy, Adoptive, Macrophage Migration-Inhibitory Factors, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, European Research Council, NIHR Great Ormond Street Hospital Biomedical Research Centre.
Abstract (Originalsprache)
INTRODUCTION: Chimeric antigen receptor (CAR) T-cell therapy is a promising and innovative cancer therapy. However, immunosuppressive tumor microenvironments (TME) limit T cell persistence and durable efficacy. Here, we aimed to identify and target immunosuppressive factors in the TME of neuroblastoma, a pediatric extracranial solid tumor, to improve CAR-T efficacy. METHODS: Immunosuppressive factors were identified using a multi-omics approach, including single-cell RNA sequencing (scRNA-seq) of 24 neuroblastoma tumors, published bulk-RNA sequencing datasets, and mass-spectrometry of patient-derived tumoroid models. Candidate targets were validated with functional assays in vitro and in vivo. Protein degradation of the top immunosuppressive target by PROTAC technology was used to evaluate the effect on CAR T-cell activity. RESULTS: ScRNA-seq revealed 13 immunosuppressive interactions in the TME of neuroblastoma, two effectors of which, Midkine (MDK) and Macrophage Migration Inhibitory Factor (MIF), were validated as candidate targets across multiple published datasets. Both factors were among the top 6 % of most abundantly secreted factors by patient-derived tumoroid models, substantiating their potential relevance in the TME. In vitro and in vivo functional assays confirmed MIF to be a potent inhibitor of CAR T-cell activation and killing capacity. To translate these findings into a potentially clinically applicable treatment, we explored MIF targeting by PROTAC technology, which significantly enhanced activation of CAR T-cells targeting GPC2 and B7-H3. CONCLUSION: By defining the immunosuppressive effects of neuroblastoma's TME on CAR T-cell efficacy, revealing the pivotal role of MIF, we provide an analytic pipeline and therapeutic strategy for improving adoptive cell therapies for this pediatric malignancy and potentially other solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
- Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia; Philadelphia, PA 19104, USA.
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A⁎STAR), 8A Biomedical Grove, Immunos, Singapore 138648, Singapore; Department of Pharmacy and Pharmaceutical Sciences, National Universi…
- Department of Chemical and Pharmaceutical Biology, Groningen, Research Institute of Pharmacy (GRIP), University of Groningen, Antonius Deusinglaan 1, Groningen 9713 AV, the Netherlands.
- UCL Great Ormond St Institute of Child Health, London, UK.
- ProCan, Children's Medical Research Institute, The University of Sydney, Westmead, NSW, Australia.
Förderung
- NCI NIH HHS
- European Research Council
- NIHR Great Ormond Street Hospital Biomedical Research Centre
- Cancer Research UK
- China Scholarship Council
- Alex's Lemonade Stand Foundation for Childhood Cancer
- KNAW
- Children's Hospital of Philadelphia
Zitieren
APA
Strijker, J. G. M., Pascual-Pasto, G., Grothusen, G. P., Kalmeijer, Y. J., Kalaitsidou, E., Zhao, C., McIntyre, B., Matlaga, S., Visser, L. L., Barisa, M., Himsworth, C., Shah, R., Muller, H., Schild, L. G., Hains, P. G., Zhong, Q., Reddel, R. R., Robinson, P. J., Catena, X., …, & Wienke, J. (2025). Blocking MIF secretion enhances CAR T-cell efficacy against neuroblastoma. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115263
Vancouver
Strijker JGM, Pascual-Pasto G, Grothusen GP, Kalmeijer YJ, Kalaitsidou E, Zhao C, et al. Blocking MIF secretion enhances CAR T-cell efficacy against neuroblastoma. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115263
BibTeX
@article{Strijker2025,
author = {Strijker, Josephine G M and Pascual-Pasto, Guillem and Grothusen, Grant P and Kalmeijer, Yannine J and Kalaitsidou, Elisavet and Zhao, Chunlong and McIntyre, Brendan and Matlaga, Stephanie and Visser, Lindy L and Barisa, Marta and Himsworth, Courtney and Shah, Rivani and Muller, Henrike and Schild, Linda G and Hains, Peter G and Zhong, Qing and Reddel, Roger R and Robinson, Phillip J and Catena, Xavier and Soengas, María S and Margaritis, Thanasis and Dekker, Frank J and Anderson, John and Molenaar, Jan J and Bosse, Kristopher R and Wu, Wei and Wienke, Judith},
title = {Blocking MIF secretion enhances CAR T-cell efficacy against neuroblastoma},
journal = {European Journal of Cancer},
year = {2025},
doi = {10.1016/j.ejca.2025.115263}
}
EUVIMED